Patents by Inventor Paul Marks

Paul Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080218566
    Abstract: Various embodiments of a metallized print head container and method are disclosed.
    Type: Application
    Filed: March 7, 2007
    Publication date: September 11, 2008
    Inventors: Craig L. Malik, Mark A. Devries, Paul Mark Haines, Ronald J. Ender
  • Publication number: 20080200082
    Abstract: A propulsion or pumping device which includes two counter-rotating shafts (3, 4) each carrying at least one impeller (7, 8), wherein each impeller (7, 8) can deflect by a predetermined amount in directions substantially perpendicular t to the longitudinal axis of the shaft (3, 4) on which the impeller (7, 8) is mounted.
    Type: Application
    Filed: May 18, 2006
    Publication date: August 21, 2008
    Inventors: Paul Mark Paterson, Barry John Davies
  • Patent number: 7389044
    Abstract: An optical network including multiple nodes is subject to intermittent faults that may raise alarms in the system. The invention focuses on an optical network based on the Any rate architecture. A single fault such as a client failure at a node in such a network can give rise to a loss of client signal leading to multiple alarms detected at multiple points. To alleviate this problem this invention provides switching in a special Signature signal in place of the lost client signal. By detecting the Signature signal containing a specific code, the fault on the any rate-based architecture can be uniquely identified. In addition to fault identification, the Signature signal on the network makes it possible to maintain Clock and Data Recovery Locks at downstream nodes. The Signature signal serves also as a vehicle for carrying a special optical tag called Wavekey provided by the Wavelength Tracker technology developed by the Applicant.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: June 17, 2008
    Assignee: Alcatel-Lucent Canada Inc.
    Inventors: David Michael Ryan Holmes, Paul Mark Reepschlager
  • Publication number: 20080131596
    Abstract: Disclosed are systems including a colorant cup that is adjacent to a cliché, wherein the cup includes a vent, an interior roof portion, and an air gap beneath the roof portion; a reservoir containing colorant; a feed conduit in fluid communication with the reservoir; and a return conduit in fluid communication with the cup. Also disclosed are various methods in which colorants are transferred in the disclosed systems from the reservoir to the colorant cup. The disclosed systems, colorant cups and methods are useful in the preparation of tinted contact lenses.
    Type: Application
    Filed: January 5, 2005
    Publication date: June 5, 2008
    Inventors: Michael F. Widman, Paul Mark Powell, Aidan Fleming, Joseph Ryan
  • Publication number: 20070190022
    Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
    Type: Application
    Filed: August 12, 2004
    Publication date: August 16, 2007
    Inventors: Nicholas Bacopoulos, Judy Chiao, Paul Marks, Thomas Miller, Carolyn Paradise, Victoria Richon, Richard Rifkind
  • Publication number: 20070155785
    Abstract: The present invention relates to a novel class of hydroxamic acid derivatives having at least two aryl containing groups, at least one of which is a quinolinyl, isoquinolinyl or benzyl moiety, linked to the hydroxamic acid group through a methylene chain. The hydroxamic acid compounds can be used to treat cancer, for example, brain cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Application
    Filed: February 22, 2007
    Publication date: July 5, 2007
    Inventors: Ronald Breslow, Thomas Miller, Sandro Belvedere, Paul Marks, Victoria Richon, Richard Rifkind
  • Patent number: 7237572
    Abstract: A check valve includes two opposing sheets surfaces that are coupled together to form a flow channel there between. The flow channel has a first end, a second end and at least one direction-changing portion in between the first and second ends. A first opening is provided at the first end of the flow channel and a second opening is provided at the second end of the flow channel.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: July 3, 2007
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventors: Paul Mark Haines, Mark A. DeVries, Ronald J. Ender, Mark Hauck
  • Publication number: 20070100559
    Abstract: The present invention provides three-dimensional structural information from the hyperthermophilic bacterium Aquifex aeolicus which is a histone deacetylase-like protein (HDLP). HDLP shares 35.2% amino acid sequence identity with human histone deacetylase (HDAC1). The present invention further provides three-dimensional structural information of HDLP bound by inhibitor molecules. The three-dimensional structural information of the present invention is useful to design, isolate and screen deacetylase inhibitor compounds capable of inhibiting HDLP, HDAC family members and HDLP-related molecules. The invention also relates to nucleic acids encoding a mutant HDLP which facilitates the determination of the three-dimensional structure of HDLP in the presence of a zinc atom.
    Type: Application
    Filed: August 16, 2006
    Publication date: May 3, 2007
    Inventors: Nikola Pavletich, Michael Finnin, Jill Donigian, Victoria Richon, Richard Rifkind, Paul Marks, Ronald Breslow
  • Publication number: 20070087427
    Abstract: The present invention provides three-dimensional structural information from the hyperthermophilic bacterium Aquifex aeolicus which is a histone deacetylase-like protein (HDLP). HDLP shares 35.2% amino acid sequence identity with human histone deacetylase (HDAC1). The present invention further provides three-dimensional structural information of HDLP bound by inhibitor molecules. The three-dimensional structural information of the present invention is useful to design, isolate and screen deacetylase inhibitor compounds capable of inhibiting HDLP, HDAC family members and HDLP-related molecules. The invention also relates to nucleic acids encoding a mutant HDLP which facilitates the determination of the three-dimensional structure of HDLP in the presence of a zinc atom.
    Type: Application
    Filed: August 16, 2006
    Publication date: April 19, 2007
    Inventors: Nikola Pavletich, Michael Finnin, Jill Donigian, Victoria Richon, Richard Rifkind, Paul Marks, Ronald Breslow
  • Publication number: 20070010669
    Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Inventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas Miller, Paul Marks, Victoria Richon, Richard Rifkind
  • Publication number: 20070010536
    Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Inventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas Miller, Paul Marks, Victoria Richon, Richard Rifkind
  • Publication number: 20060241129
    Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
    Type: Application
    Filed: June 22, 2006
    Publication date: October 26, 2006
    Inventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas Miller, Paul Marks, Victoria Richon, Richard Rifkind
  • Publication number: 20060110247
    Abstract: An article of manufacture pattern for improving aerodynamic performance of a turbine including an abradable material capable of abradable contact. The abradable material is disposed in a pattern. The pattern includes a first plurality of ridges disposed at a base surface of the turbine. Each ridge of the first plurality of ridges has a first sidewall and a second sidewall having a first end and a second end. The first ends of the first and second sidewalls extend from the base surface. The first and second sidewalls slope toward each other with substantially equal but opposite slopes until meeting at the second ends of respective first and second sidewalls defining a centerline and a top portion of the ridge.
    Type: Application
    Filed: April 22, 2005
    Publication date: May 25, 2006
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Warren Nelson, Brian Arness, Paul Marks, Raymond Chupp, Tara McGovern
  • Publication number: 20060110248
    Abstract: A pattern for improving aerodynamic performance of a turbine includes a material disposed in a pattern at a base surface of a turbine shroud such that the material is capable of abradable contact with a tip portion of a turbine bucket. The pattern includes a first plurality of ridges disposed at the base surface such that a first portion of the first plurality of ridges corresponding to a back portion of the turbine bucket is oriented at a first angle with respect to an axis of rotation of the turbine bucket. Each ridge of the first plurality of ridges has a first sidewall and a second sidewall having a first end and a second end. The first ends of the first and second sidewalls extend from the base surface. The first and second sidewalls slope toward each other with substantially equal but opposite slopes until meeting at the second ends of respective first and second sidewalls defining a centerline and a top portion of the ridge.
    Type: Application
    Filed: November 24, 2004
    Publication date: May 25, 2006
    Inventors: Warren Nelson, Brian Arness, Paul Marks, Raymond Chupp, Tara McGovern
  • Publication number: 20060079551
    Abstract: The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. The individual can be a mammal such as a primate or human.
    Type: Application
    Filed: November 18, 2005
    Publication date: April 13, 2006
    Inventors: Victoria Richon, Paul Marks, Richard Rifkind
  • Patent number: 7014839
    Abstract: The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: March 21, 2006
    Assignee: Amersham Health AS
    Inventors: Jo Klaveness, Bjorn Fuglaas, Pål Rongved, Edvin Johannesen, Paul Mark Henrichs, Wolfgang Hans Heinrich Gunther, Edward Richard Bacon, John Luke Toner, Gregory Lynn McIntire, Vinay C. Desai
  • Publication number: 20060030019
    Abstract: The present invention features substantially pure HDAC9, HDAC9a, HDAC9(?NLS), HDAC9a(?NLS), an HDRP(?NLS) polypeptides, and isolated nucleic acid molecules encoding those polypeptides. The present invention also features vectors containing HDAC9, HDAC9a, HDAC9(?NLS), HDAC9a(?NLS), and HDRP(?NLS) nucleic acid sequences, and cells containing those vectors.
    Type: Application
    Filed: August 10, 2005
    Publication date: February 9, 2006
    Inventors: Victoria Richon, Xianbo Zhou, Richard Rifkind, Paul Marks
  • Publication number: 20060009527
    Abstract: The present invention provides a novel method for treating and/or preventing thioredoxin (TRX)-mediated diseases and conditions, by administering to a subject in need of such treatment a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof. The HDAC inhibitor can alter the expression of a thioredoxin-binding-protein (e.g. TBP-2), which in turn can lead to an altered TRX/thioredoxin-binding-protein cellular binding interaction, resulting in an increase or decrease in the level or activity of cellular TRX, for example the expression level or reducing activity of TRX. Thus the present invention relates to the use of HDAC inhibitors in a method of preventing and/or treating a wide variety of thioredoxin (TRX)-mediated diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.
    Type: Application
    Filed: September 9, 2005
    Publication date: January 12, 2006
    Inventors: Victoria Richon, Paul Marks, Richard Rifkind, Lisa Butler
  • Publication number: 20060009526
    Abstract: The present invention provides a novel method for treating and/or preventing thioredoxin (TRX)-mediated diseases and conditions, by administering to a subject in need of such treatment a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof. The HDAC inhibitor can alter the expression of a thioredoxin-binding-protein (e.g. TBP-2), which in turn can lead to an altered TRX/thioredoxin-binding-protein cellular binding interaction, resulting in an increase or decrease in the level or activity of cellular TRX, for example the expression level or reducing activity of TRX. Thus the present invention relates to the use of HDAC inhibitors in a method of preventing and/or treating a wide variety of thioredoxin (TRX)-mediated diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.
    Type: Application
    Filed: September 9, 2005
    Publication date: January 12, 2006
    Inventors: Victoria Richon, Paul Marks, Richard Rifkind, Lisa Butler
  • Publication number: 20050288227
    Abstract: The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.
    Type: Application
    Filed: June 3, 2005
    Publication date: December 29, 2005
    Inventors: Paul Marks, Johanna Ungerstedt